Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Strong underlying insulin market growth and sustained
global volume market share
Slide 48
Global modern and new-generation insulin
volume market shares
Novo Nordisk
Sanofi
-
Eli Lilly
Global insulin market
Device penetration
Modern insulin penetration¹
tMU
Penetration
500
CAGR volume²: 4.4%
100%
60%
CAGR value²: 16.8%
50%
400
80%
40%
300
60%
MI and NGI¹
30%
200
- 40%
20%
100
20%
Human insulin
10%
0
0%
0%
Nov
2012
Nov
2017
Nov
2012
1 MI: Modern insulin. NGI: New-generation insulin 2 CAGR for 5-year period
Note: Data is sensitive to changes in IQVIA data collection and reporting methodology.
Source: IQVIA (formerly IMS) monthly MAT Nov, 2017 volume and value (DKK) figures
changing
Note: Data is sensitive to changes in IQVIA data collection and reporting methodology,
does not add up to 100% as only selected pharmaceutical companies are included
Source: IQVIA (formerly IMS) monthly MAT Nov, 2017 volume figures
diabetes®
45%
34%
20%
Nov
2017
novo nordiskView entire presentation